Sajad Dehnavi

Dr. Sajad Dehnavi


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2022 in Phytotherapy Research
Verified
Journal Article
Open access
PDF file
AAAli Asadirad
Ali Asadirad
RNRoohangiz Nashibi
Roohangiz Nashibi
AKAli Khodadadi
Ali Khodadadi
AGAta A Ghadiri
Ata A Ghadiri
MSMahvash Sadeghi
Mahvash Sadeghi
SDSajad Dehnavi
Sajad Dehnavi
The present study conducted a placebo‐controlled clinical trial to evaluate the impact of nano‐curcumin on the inflammatory cytokines in mild‐to‐moderate hospitalized COVID‐19 patients. A total of 60 COVID‐19 patients were randomly divided into nano‐curcumin and control groups, and then they received 240 mg/day nano‐curcumin for 7 days. The clinical manifestation and laboratory parameters in patients were recorded on days 0 and seven. Also, SYBR Green real‐time PCR and ELISA techniques were implicated in assessing the mRNA expression of IFN‐γ, IL‐1β, IL‐6, MCP‐1, and TNF‐α and the serum levels of IL‐1β, IL‐6, and TNF‐α inflammatory mediators, respectively. Although the clinical manifestations and laboratory parameters improved via the nano‐curcumin treatment, the mRNA expression of IFN‐γ (p = 0.006) and TNF‐α (p = 0.04) were significantly reduced. Besides, a considerable difference was observed between the nano‐curcumin and control groups in the expression of IFN‐γ (p = 0.001), IL‐1β (p = 0.0002), and IL‐6 (p = 0.008). In addition, there was a significant difference between the nano‐curcumin and control groups in the serum levels of IL‐1β (p = 0.042). The evidence demonstrated that nano‐curcumin could be implicated as a complementary medication to act as an antiinflammatory agent and inhibit inflammatory complications.

2 June 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
AAAli Asadirad
Ali Asadirad
AGAta.A. Ghadiri
Ata.A. Ghadiri
AAAfshin Amari
Afshin Amari
MDMohammad Ghasemi Dehcheshmeh
Mohammad Ghasemi Dehcheshmeh
MSMahvash Sadeghi
Mahvash Sadeghi
SDSajad Dehnavi
Sajad Dehnavi

29 October 2025 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
MDMohammadreza Dashti
Mohammadreza Dashti
MSMorteza Mohammaddust Sarab
Morteza Mohammaddust Sarab
FSFaezeh Shad
Faezeh Shad
SDSajad Dehnavi
Sajad Dehnavi
Mesenchymal stromal/stem cells (MSCs) have introduced as a cornerstone of regenerative medicine, owing to their immunomodulatory properties and therapeutic potential in autoimmune and inflammatory disorders. Although, their clinical application is often restricted due to immune rejection and heterogeneity in immunoregulatory responses. The advent of Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR/Cas9) technology has revolutionized MSC engineering, enabling precise genetic modifications to enhance their immunological efficacy. This review explores how CRISPR-mediated editing of MSCs can mitigate immunogenicity, amplify anti-inflammatory functions, and repurpose MSCs for targeted immunotherapy. Key strategies include knockout of β2-microglobulin to evade T-cell recognition, augmentation of anti-inflammatory mediators like interleukin (IL)-10 and TNF-alpha stimulated gene/protein 6 (TSG-6), and disruption of pro-inflammatory pathways such as toll-like receptor 4 (TLR4)/NF-κB. In addition, CRISPR-engineered MSCs demonstrate promise in reshaping tumor microenvironments and combating bacterial infections through enhanced innate immunity. Despite challenges including off-target effects and delivery optimization, CRISPR-tailored MSCs represent a transformative approach to overcoming immunological barriers, paving the way for universal, off-the-shelf therapies in rheumatoid arthritis, cancer, and beyond.

14 May 2025 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
MDMohammadreza Dashti
Mohammadreza Dashti
MMMojgan Mohammadi
Mojgan Mohammadi
SDSajad Dehnavi
Sajad Dehnavi
MSMahvash Sadeghi
Mahvash Sadeghi
Psoriasis is defined as a persistent autoimmune disease characterized by the appearance of psoriatic lesions on the surface of the skin. Currently, various approaches including chemicals, corticosteroids, phototherapy, and biological agents are being proposed and implemented to improve psoriatic lesions by modulating immune system activity or metabolic processes, often with unintended consequences and side effects. Currently, mesenchymal stromal/stem cells (MSCs) have attracted considerable interest among researchers due to their ability to modulate immune responses and their ease of application, representing a promising strategy for alleviating clinical symptoms in the treatment of allergic reactions, autoimmune diseases, cancer, and more. This study will investigate how MSCs interact with immune system cells involved in psoriasis development, such as neutrophils, keratinocytes, dendritic cells (DC), and T cell subtypes, for potential therapeutic use in psoriasis management. In this case, several immunomodulatory mechanisms are involved, including expression of chemokines, pro-inflammatory cytokines, matrix metalloproteinase and other factors involved in cell proliferation and neutrophil extracellular trap (NET) formation are among the effects of MSCs on keratinocytes and neutrophils. keratinocytes and neutrophils as pro-inflammatory cells involved in psoriasis pathogenesis and pathogenesis and progression of psoriasis. On the other hand, MSCs interact with DCs and various subsets of T cells, including Th1, Th2, Th17 and Tregs, to generate tolerogenic DCs and increase the differentiation of Tregs and modulate the Th17/Treg towards a regulatory state through overexpression of anti-inflammatory and immunomodulatory and immunomodulatory cytokines, including IL-10 and transforming growth Factor beta (TGF-β). Finally, we will focus on the challenges and obstacles in psoriasis treatment using MSCs, including limitations in the case of using MSCs from different sources and side effects that may be encountered by whole cell therapy strategies, which are attracting attention towards the implication of cell-free regimens such as using MSC-derived secretome or extracellular vesicles and exosomes to provide similar therapeutic outcomes without presumed side effects.

8 February 2025 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
MSMahvash Sadeghi
Mahvash Sadeghi
AMAsma Moghaddam
Asma Moghaddam
AAAmir Mohammad Amiri
Amir Mohammad Amiri
KCKianush Charoghdoozi
Kianush Charoghdoozi
MMMojgan Mohammadi
Mojgan Mohammadi
MOMahmoud Orazizadeh
Mahmoud Orazizadeh

23 May 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
MGMohammad Gholami
Mohammad Gholami
KGKhodayar Ghorban
Khodayar Ghorban
MSMahvash Sadeghi
Mahvash Sadeghi
MDMaryam Dadmanesh
Maryam Dadmanesh
NRNegin Hosseini Rouzbahani
Negin Hosseini Rouzbahani
SDSajad Dehnavi
Sajad Dehnavi